| ●Editorial | Fukushima M | 422-3 |
| ●The 8th Translational Research Educational Program Current status and future scope of somatic stem cell therapeutics ─ To be autologous, or to be allogeneic ─ Organized by：Foundation for Biomedical Research and Innovation |
425-90 | |
| Opening remarks | Fukushima M | 427-30 |
| Key Factors for Success and Issues in Commercializing Regenerative Medicine in Japan | Ozawa Y | 431-41 |
| How should the product development be performed, utilizing the clinical study? Development of a corneal epithelial cell sheet | Kitagawa A | 442-56 |
| Autologous Adipose-Derived Regenerative Cells (ADRCs) for acute myocardial infarction and chronic myocardial ischemia | Fraser JK | 457-64 |
| Umbilical cord derived MSCs and their clinical potential | Viswanathan C | 465-85 |
| Discussion | 486-90 | |
| ●Public Debriefing Session 2009 Current status of regenerative medicine clinical research Organized by：Foundation for Biomedical Research and Innovation | 491-599 | |
| Annual Reports of Translational Research 2009 ─ With special reference to regenerative medicine ─ | Saruta T | 494 |
| Medical technology R&D tracks and TR Center infrastructure in Japan | Nagai Y | 495-501 |
| New world which is realized after the TR promotion program: R&D pipeline of the academic sector in Japan | Fukushima M | 502-9 |
| Current status of cell therapy in the US and India: Overview | Koga T | 510-2 |
| Therapeutic angiogenesis for critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel | Marui A，Tabata Y，Inui K，et al. | 513-9 |
| Research and development of a novel RNA drug based on recombinant Sendai virus for the treatment of peripheral arterial disease | Yonemitsu Y，Yoshida K，Uchiyama M，et al. | 520-6 |
| Intravenous injection of autologous mesenchymal stem cells derived from bone marrow into stroke patients | Honmou O，Onodera R | 527-31 |
| A new therapeutic strategy for treatment of patients with spinal cord injury using bone marrow stromal cells | Suzuki Y，Nakatani T，Ide C，Fukushima M | 532-6 |
| Clinical trial of hybrid biotherapy via autologous human cardiac stem cell transplantation combined with left ventricular assist device to treat severe refractory heart failure | Takehara N，Matsubara H，Yaku H，et al. | 537-48 |
| Development of a new strategy for severe heart failure using aoutologous myoblast sheets | Saito A，Miyagawa S，Sawa Y | 549-57 |
| Longterm outcomes of cultivated oral mucosal epithelial transplantation | Sotozono C，Inatomi T，Nakamura T，et al. | 558-64 |
| Corneal reconstruction with autologous oral mucosal cells ─ A multi-center clinical study | Nishida K | 565-70 |
| Development of new therapy using mesenchymal stem cells for osteonecrosis | Toguchida J | 571-83 |
| Bone regenerative medicine ─ Local transplantation of G-CSF-mobilized CD34+ cells in patients with nonunion ─ | Kuroda R，Kurosaka M，Asahara T，Matsumoto T | 584-8 |
| Identification of liver repair cells from bone marrow | Sakaida I，Miyajima A，Ogawa Y，et al. | 589-92 |
| Development of a novel protocol for alveolar bone tissue engineering using cultured autologous osteoblast-like cells | Kagami H | 593-9 |
| ●Study report | ||
| Stem cell clinical trials in the world, 2010 | Nishimura T，Ohno T，Nishimura H，et al. | 601-13 |
| ●Proposal | ||
| Right budget allocation for promoting translational research; Japan needs to change budget allocation mechanism for public benefit |
Ohno T，Nagai Y，Fukushima M | 615-21 |
| ●Forum | ||
| Report of the participation in the U. S. Society of Nuclear Medicine Clinical Trial Network Summit meeting |
Kurihara C | 623-8 |
| ●Instructions for authors [Japanese] & [English] | 629-34 | |
| ●Editor's note | Tsubaki H | 635 |